We chose to contact CS Medica as we see great advantages in being a First-Mover into the Asian market and the natural synergies between their medical technology platform and our production capacity and distribution network. We have recently noticed that the market in Asia has matured and is now ready for CBD-products, and we are at the end of our Due Diligence and looking forward to taking further steps ahead. Our ambition is to be a strong long-term partner.

I really look forward to discussing the process and joint venture further with Rong Shi when they visit us later the year.

"We are happy to announce that CS MEDICA is closing the year with 10,6M DKK in revenue, and we are proud of the strong partnerships we have developed in the last months. We have moved from being an R&D to a commercialized company, now listed in most pharmacies in DK, on Amazon, and we have signed with distributors in Israel, Hong Kong, Slovenia, Croatia, and Serbia to market our Cannasen® brand. The latest distribution partner we have teamed up with is Alliance Healthcare Romania, part of the Alliance Healthcare, one of the largest wholesalers in Europe, supplying more than 115,000 pharmacies, doctors, and health centers in 13 countries. This order includes our full Cannasen® portfolio incl. the new Wound Gel." 

We are happy to have this huge investment interest from the Asian market, and Inner Mongolia Rong Shi Hi-Tech Co. as well as us are aiming for a quick due diligence as we hope to get into operation as soon as possible

CS MEDICA are happy to announce that we found a strong partner, with the right strategy in place, to kick start sales in several Balkan countries. We see this as an opportunity to step into a region, not easily accessible without the know-how in the market. Also, this as an option to further develop the Balkan and Eastern EU presence in near future.

Ampilio has done a great job helping us launch on both the Swedish and German Amazon; however, we experience products containing CBD need a different strategy and communication. The speed to market has been too slow; consequently, we agreed to move our partnership to Incubeta Maze-One, a preferred Amazon partner like Ampilio, but who is familiar working with CBD brands on Amazon.

We work with several Nordic brands within personal care, including CBD-based products, where we see an increasing sales potential in Europe. Selling CBD-based products on Amazon comes with certain compliance demands that require special solutions and communication tactics. We look forward to working with CS MEDICA to build and grow Amazon as a sales channel.

We are looking forward to starting the process preparing the CS MEDICA’s shares to the Main Market in Denmark.

We are happy we launched at Spotlight as a nano/microcap company in an early growth phase, and the support has been outstanding. However, as we have finalized the main clinical trials, we are rapidly reaching international territories with our finished, registered products plus the technology and science behind the formulas and CBD know-how, allowing us to reach further segments. Combined with the fact we have a first mover advantage, being ahead of the competition on registrations from MDD to MDR, we need to capitalize now. Hence, we need to prepare for the next growth phase, and have been recommended to start the process of moving to the Main Market

Alsitan has had a very successful market reception of the arthritis gel in the German market and is now expanding their portfolio with another white label CANNASEN product - a new advanced arthritis pain gel. Together with Alsitan, who are experts in their field, this order gives us a unique opportunity to better match our product portfolio to the market dynamics. We see this not only as proof of concept, but also proof of business.

he registration at the MHRA in the UK is an important step for CS MEDICA as the UK works as a display market for Australia, MENA (Middle East and North Africa) and other countries where the local health authorities use the UK as a reference country. Hence the MHRA registration is an significant mark in our efforts to create global awareness and sale

We are very pleased with the successful warrant exercise. We welcome all new and existing shareholders on our continued journey ahead.

We are proud to announce, that we finally made it to the pharmacies, with agreement signed with two of the three leading pharmacy chains in Denmark. We will use and optimize this new position in the market by accelerating our listings and built brand stores on the growing players within the online pharmacy channel.

We are very proud to be able to become the first legal CBD brand to enter the Israeli market, notably as Israel is one of the global leaders within the area of CBD and Cannabis research. We look very much forward to our collaboration with our strong partner in Israel, Forbe HealthCare Ltd., and we are confident that we together will develop a strong success story in the Israeli market.

I am very pleased to announce that CS MEDICA has expanded their product portfolio now also covering protection against COVID-19 virus infection. This opens a new market for the Company which has a huge market potential with the fall being just around the corner and thereby also a season for COVID-19.

We strongly believe in CS MEDICA’s bright future and by extending our lock-up agreement it reconfirms our commitments to the future development of the Company and we have no intention of selling our shares now

One of the things to secure when building a global business is trademarks. CS Medica has always been active in filing patents to secure the future for our products, but we also see the value of securing our brands with trademark registration. This is an additional important step we are taking in our global sales strategy.

This clinical study results, mark another important step for CS MEDICA and continues our strong track record for delivering impactful products. It gives us a unique position in the market as first mover with proven effective and safe Medical CBD products. It paves the way for further R&D of products within this category and gives us a solid foundation to build our commercial track record. These results combined with the patents pending and trademark foresee a high value & revenue in the years to come. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel & CANNASEN®CBD ARTH Supplement in combination are proving to be both safe and efficient for patients and most important our CANNASEN®CBD Arthritis Gel & CANNASEN®CBD ARTH Supplement improves the overall quality of life for patients with Osteoarthritis.

We are glad to see that our hard efforts are paying off with the further expansion of our sales channels and that we are now also represented in Germany by Amazon. We see that this is a growing market with great potential.

I am very glad to announce that CS MEDICA continues to expand on the European market. The Agreement with NaturaMedica demonstrates that our products are wanted and gives us a broader customer base in Europe. We hope that this agreement will spark more interest around Europe as we continue our expansion.

We are proud to announce that we have signed our first agreement that covers both the market in Israel and Palestine. For CS MEDICA, the signing of this agreement demonstrates the capabilities of our products and will be a key part of helping us reaching our financial goals in the years to come. I am proud that we continue to break ground on the global market and that our expansion is continuing.

The clinical study results mark an important step for CS MEDICA as we continue our strong track record for delivering impactful products. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel is proving to be both safe and efficient for patients and most important our CANNASEN®CBD Arthritis Gel improves the overall quality of life for patients with osteoarthritis.

We were proud to be selected to showcase our unique and innovative products at the Vitafoods event. We feel that our products were highlighted especially as our products represented the only medical device brand with products containing CBD. We engaged in several interesting discussions and we found our participation very productive, especially with the global presence of different partners.

Our previous white label order received from Alsitan, a total of 40,000 units of the Arthritis gel had a very successful market reception at the German market and is now sold out. Following the successful market launch we have now entered into a private label agreement with Alsitan, covering the German and Austria territory. The agreement, covering the Arthritis gel launched under the brand name “Alsiroyal”, is based on minimum orders, in year 1 and 2, of 40,000 units and in 2024 at 60,000 units. The agreement automatically continues beyond the 3 years, after which new minimum orders are to be set.”

We are very proud of finally breaking ground in a bigger scale. With our agreement with, Chinese based CBF SciTech Ltd, we now lift our business to a new level. We are now beginning to reap the reward of all our efforts, and I strongly believe that this is only the beginning.

I am happy to welcome Heidi Ahlefeldt-Laurvig as CGO/CMO. Heidi has extensive experience in marketing and digitalization and possesses a rare toolbox encompassing a complete set of skills corresponding to our ambitions. With Heidi's expertise, I am confident that she will be an important asset in our continued growth journey.

The validation of CANNASEN® being officially confirmed as a trademark in the US is of key importance for our strategy going forward in the North American market.”

Although we are not in need of the funding coming from the DIAZ Direct issue, we saw an opportunity that we could not overpass. With the agreements, with and cooperation network of DIAZ altogether focusing on future growth, and the kick start of our Investor Relation area, we secure a more thorough understanding of the company and the possibilities within the business area of CS MEDICA.

The strategy to build strong customer relationships drive sales, sustainability, and growth, this is something we see that the SpectrumOne group has delivered for their clients’ time and time again so our choice to work with them couldn’t have been easier, we have one of the best revolutionary CBD medical products on the market and with Ampilios help they will deliver this message to the world market and create lifelong relationships with our customers.

For a company providing pharmaceutical products containing cannabis and cannabinoids, this initiative is very satisfactory as it 'eases' the regulatory situation and shows a form of market acceptance. We hope that Germany will mark the starting point for further legislation processes in Europe. These legislations are of great importance and can have potential effects on the operations of CS MEDICA. The effects are not only connected to the market growth of our current product portfolio but also the upcoming dispenser product line. Legislations like these symbolize a sense of acceptance for our industry and we are glad that the market trends are moving in the right direction.

We are glad that the Danish Parliament has expressed their support for the cannabis industry in Denmark. This regulation reflects positively on our business as these regulatory reforms will increase the awareness of medical cannabis and hopefully allow the industry to grow even more. We feel confident that this news will have a positive impact on the industry and market in which we operate while also decreasing a risk factor for our company.

We are experiencing great interest in our product portfolio. However, following the clinical delays in India, we are delayed in negotiations with a potential customer. We expect to finalize the agreement in 2022. However, as a result, we will not achieve our financial target for the fiscal year 2020/2021. Instead, the expected agreement will have a positive impact on the results for 2021/2022. We see no reason to revise our future objectives”, comments Lone Henriksen, CEO of CS MEDICA.

As this is our first order by a private label customer, we are very excited. This agreement signifies the potential for further advances in the private label field and further follows our communicated financial expectations for our business.

“The intermediate study results mark an important step for CS MEDICA and continues or strong track record for delivering impactful products. We are proud to share these results as the trial shows that the CANNASEN®CBD Arthritis Gel is proving to be both safe and efficient for patients.”

“I am proud to announce that the issue of units prior to our listing was oversubscribed. The strong interest in our business strengthens us as we proceed with our work. I want to welcome the new shareholders on board as we move towards the listing on Spotlight Stock Market and onwards, continuously scaling the business while entering new markets and growing our product portfolio.”

"We are happy to be approved for listing on Spotlight Stock Market. Our vision as a public company is to improve the wide public's life quality by offering effective and safe treatment solutions. We aim to be in constant development, exploring how CS MEDICA can support patients in their battle against disease, pain, and the sorrow it brings. The listing and forthcoming IPO are important steps for CS MEDICA as we continue with our work to reach our targets for the operation, primarily focusing on advancing across the European market, and continuing our research, and development activities. Moving ahead, we want to further our advancements working with carefully selected partners to establish our CANNASEN® product lines across European borders.”